Plasma levels of neurofilament light chain (NfL), phosphorylated tau (pTau) 181 and pTau 231 all showed a smaller increase in blarcamesine-treated patients compared to placebo, but did not reach statistical significance.
← all excerpts
Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials.
1
—
—